Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype containing the NMDA receptor subunit 2B (NR2B), inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase, increased expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrKB), and activation of the mammalian target of rapamycin (mTOR) signaling pathway, alongside other independent actions attributed to the ketamine metabolism to R-hydroxynorketamine (R-HNK). The enantiomer S-ketamine (esketamine) displays approximately fourfold greater affinity for the glutamate NMDA receptor in vitro than R-ketamine. Proof-of-concept single-dose and repeat-dose studies with intravenous ketamine show a significant antidepressant and probably antisuicidal effect in the short term, with response rates over 60% as early as 4.5 h after a single dose, with a sustained effect after 24 h, and over 40% after 7 days. This response can be further sustained over several weeks with repeated doses (two to three doses per week). Tolerability seems acceptable in the short term, with transient elevation of blood pressure and mild and transient dissociative and p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longer term safety signals are still emerging, including concerns related to abuse liability, urinary symptoms, and cumulative neurocognitive effects with repeated exposure [82,86,90].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“Dissociative and psychotomimetic effects are common, typically transient, and sometimes accompanied by cardiovascular changes [85,86,87].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“These acute and transient effects include an increase in blood pressure (usually asymptomatic), nausea and vomiting, perceptual disturbance, drowsiness, dizziness and dissociation.43,76–78”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [76]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870
Research works printed but not linked: 1
- Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2215036617302729 .
Cited by
Items 201–290 of 290
Pharmacological treatment of adolescent depression: Current advances and future perspectives
Li, Y., Wang, F., Chen, G., & Zhai, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100278 · Cited by 3
Inflammation in treatment-resistant depression: From mechanisms to therapeutics
Wu, S., Gao, X., Zhou, Y., Lin, Z., Chen, C. H., Luo, J., Liu, X., Lin, L., 邵红伟, & Liu, S. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111953 · Cited by 3
Akash, K., Ahmad, M., Nadeem, M. S., Khan, A. M., Kashif, M. A. B., Rajpar, N. A., Madhwani, N., Ladhwani, N. K., Raza, A., REHMAN, A. U., et al. (2025) · Minerva Anestesiologica · doi:10.23736/s0375-9393.25.18906-2 · Cited by 3
(2021) · Letters in Applied NanoBioScience · doi:10.33263/lianbs113.36403651 · Cited by 4
“Ketamine and esketamine is a fast, significant stimulant effect and the plausible against a self-destructive effect that was transient when restricted to single administration [74].”
BackgroundExploring the potential of drug repurposing for treating depression
Verma, C., Jain, K., Saini, A., Mani, I., & Singh, V. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.037 · Cited by 3
Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches
Limandri, B. J. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20180920-02 · Cited by 3
Confounders Not General Anesthesia Likely Explain Greater Postpartum Depression
Ansari, J. R., Carvalho, B., Weiniger, C. F., & Riley, E. T. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004850 · Cited by 3
Karakatsoulis, G. N., & Fountoulakis, K. Ν. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_8 · Cited by 4
The NMDAR-BK channelosomes as regulators of synaptic plasticity
Lázaro, R. M., Reyes-Carrión, A., Bartolomé-Martín, D., & Giráldez, T. (2025) · Biochemical Society Transactions · doi:10.1042/bst20240425 · Cited by 2
Ju, L. I. U., Zhang, Y., Zhang, R., Yuwen, W. A. N. G., Peng, G. U. O., Hong, C. H. E. N., Hu, X., & Wu, Y. (2025) · Minerva Anestesiologica · doi:10.23736/s0375-9393.25.19237-7 · Cited by 2
Merola, A., Mukai, Y., Bueters, T., Ceesay, P., Dupre, N., Furtek, C. I., Sanacora, G., Thase, M. E., Targum, S. D., Smith, S. M., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002171 · Cited by 2
Degroot, A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00002-3 · Cited by 2
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 3
Self-citationWang, J., Du, Y. J., Tan, Y.-S., Liu, Y., & Wen, A. P. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/1327019 · Cited by 2
“S-ketamine has been reported to possess both analgesic and antidepressant properties, which could potentially beneft patients experiencing postoperative depression [27].”
Depression in New Mothers, Volume 2: Screening, Assessment, and Treatment Alternatives
Kendall-Tackett, K. A. (2024) · Routledge eBooks · doi:10.4324/9781003405092 · Cited by 3
Kumar, V., & Doshi, G. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138169 · Cited by 2
Jiang, K., Zhao, W.-Q., Ying, Y.-Y., Zhuang, M.-Y., Shi, H.-J., Ji, F., & Peng, K. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2478479 · Cited by 2
Guanine-Based Purines as an Innovative Target to Treat Major Depressive Disorder
Almeida, R. F., Ferreira, T. P., David, C. V. C., Silva, P. C. A. E., dos Santos, S. A., Rodrigues, A. L. S., & Elisabetsky, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652130 · Cited by 3
“, 2016), protein synthesis, and synaptic plasticity (Zanos et al., 2016; Molero et al., 2018).”
BackgroundPharmacological assistance for psychotherapy
Lochtenberg, J., Kirshenbaum, A. P., & Johnson, M. W. (2021) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2021.100017 · Cited by 3
Parmaki, S., Ferreira, F. C., Esteves, T., Afonso, C. A. M., & Koutinas, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89855-3.00006-6 · Cited by 3
Treatment-resistant psychotic depression
Koretski, J. A., & Rothschild, A. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00024-4 · Cited by 2
Gowthami, B., Mehta, I., Baiju, S., Appani, A., Suvarna, T., Randhawa, K., Kakkad, A. M., Syed, A. B., Kumar, V., Ramteke, H. D., et al. (2025) · medRxiv · doi:10.1101/2025.09.22.25336317 · Cited by 2
Esketamine for Treatment-Resistant Depression in Pakistan: A Promising Strategy
Memon, M., Gul, R., Gul, A., Bansari, S., Bansari, M., Khowaja, A., Kumar, S. G., Kumar, K., Khan, K. S., Iman, K., et al. (2025) · Hospital Pharmacy · doi:10.1177/00185787251384516 · Cited by 2
Kapfhammer, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-65873-4_1 · Cited by 1
Almeida, T. M., Rosa, D. A. A., Pinheiro, T. B., Grilo, L. B., Jorge, G. M. T., Foletto, L. D., Generoso, I. P., da Silva, U. R. L., Uchida, R. R., & Cordeiro, Q. (2024) · Psychiatry Research Communications · doi:10.1016/j.psycom.2024.100190 · Cited by 1
KETAMINE: Neural- and network-level changes
Bharmauria, V., Ramezanpour, H., Ouelhazi, A., Belkacemi, Y. Y., Flouty, O. E., & Molotchnikoff, S. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.010 · Cited by 1
Zhang, L., Bao, D., & Wang, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116490 · Cited by 1
Yin, H., Wang, S., & Huang, H. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-114079 · Cited by 1
Zhu, H., Wei, Q., Xu, S., Sun, Y., Liu, X., Zhu, J., & Yu, Y. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03929-3 · Cited by 1
“…antidepressant response, esketamine shows higher potency, enhanced receptor af fi nity, and a reduced prevalence of adverse reactions in the nervous system relative to ketamine [13], rendering it a preferable option for preventing and treating depressive symptoms during the perioperative period.”
García-Jiménez, J., Núñez-Arias, D., Merelo, G. C., Miller, A., Romero, A. M., Gutiérrez-Rojas, L., & Mesones-Peral, J. E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261430495 · Cited by 1
“In contrast, Ketamine and ESK NS have demonstrated rapid reductions in suicidal ideation, with some effects observable within hours, and sustained improvements during follow-up (Canuso et al., 2018; Ionescu et al., 2021; Molero et al., 2018).”
Self-citationChawla, G., Pradhan, T., Alam, N., Kunzang, S., & Gupta, O. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70251 · Cited by 2
Guidetti, C., Fava, M., & Papakostas, G. I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03722-0 · Cited by 1
Alamoudi, A. J. (2026) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-026-00101-2 · Cited by 1
“…in many diseases, including Alzheimer’s disease (AD) (Mota et al. 2014), Huntington’s disease (HD) (Zhang et al. 2025), major depressive disorder (Molero et al. 2018), tinnitus (Noreña, 2015), migraine (Ye et al. 2009) epilepsy, stroke, and traumatic brain injury (Zhou and Sheng 2013), where…”
Feifel, D., Seynaeve, M., Cubała, W. J., Dunbar, F., Gründer, G., Herrero, R. M. D., Hindocha, C., Liknaitzky, P., Mcguigan, S., Mehta, S., et al. (2026) · JAMA · doi:10.1001/jama.2026.18380 · Cited by 1
Ketaminaren eragin antidepresiboak. Ekintza mekanismo berriak farmako antidepresiboen bilaketarako
Roman, L. B., Saumell-Esnaola, M., Isasti, A., Aretxabala, X., González‐Burguera, I., de Jesús, M. L., del Caño, G. G., Sallés, J., & Barrondo, S. (2019) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.20145 · Cited by 1
Intranasal esketamine in treatment-resistant depression: a profile of its use
Scott, L. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00675-z · Cited by 1
The role of ketamine in the treatment of treatment-resistant bipolar depression
Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.052 · Cited by 1
À propos de l’utilisation du traitement de la kétamine aux urgences psychiatriques
Sergentanis, I. N., Vibert, V., Costanza, A., Néris, M. D., Besson, M. J., Kosel, M., Bondolfi, G., & Ambrosetti, J. (2021) · JMIG · doi:10.53738/revmed.2021.17.725.0303 · Cited by 1
Mehta, P., Dhar, R., & Messias, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33264-8_7 · Cited by 1
An, Y., Park, S.-Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.243 · Cited by 1
Gu, X., Han, Y., Qian, B., & Yin, D. (2022) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2022.123210 · Cited by 1
“Moreover, epidural ketamine has been shown not to induce cardiovascular depression, and it is associated with beneficial ef fects such as preventing shivering, ob turator nerve reflex, nausea, and any other adverse effects, which suggests ketamine should be an advantage in urological surgery of patients with cardiop…”
BackgroundSub-Anesthetic Dose of Ketamine Improves Cognitive Function and Motor Responses in Wistar Rats
Uahomo, P. O., Ibubeleye, V. T., Ezerioha, C. E., & Adheke, O. M. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v19i4380 · Cited by 1
Ketamine for Treatment of Addiction in Alcohol, Opioid, and Cocaine Use Disorder
Vujović, K. S., Jotic, A. D., Medić, B., & Cirkovic, I. B. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_19 · Cited by 1
Stein, H., Strawbridge, R., Silman, D., Carmellini, P., Young, A. H., & Juruena, M. F. (2023) · medRxiv · doi:10.1101/2023.02.09.23285702 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Ketamin in der Behandlung depressiver Episoden
Deuschle, M., & Gilles, M. (2018) · Nervenheilkunde · doi:10.1055/s-0038-1670570
“Dennoch stellt auch intranasales Esketamin (31, 32) oder orales Ketamin (33, 34) keine in Deutschland zugelassene Behandlung für Depression dar (35).”
BackgroundPrevalencia y factores asociados a la depresión mayor en Andalucía
Porras‐Segovia, A. (2019) · Institutional Repository of the University of Granada (University of Granada) · Cited by 2
Part I: Optimizing treatment with antidepressants
Jhawar, A., Parmentier, B. L., & Grady, S. E. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1213
Farhana, M. S., Dhivagar, S., & Prabavathy, S. (2020) · Pondicherry Journal of Nursing · doi:10.5005/jp-journals-10084-12137
Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Ketamine: use in psychiatry, its pharmacology and treatment following intoxication
Oruch, R., Pryme, I. F., Fasmer, O. B., & Lund, A. (2021) · Minerva Psychiatry · doi:10.23736/s2724-6612.21.02068-9
Introductory Chapter: Is Ketamine the New Panacea of the 21 st Century?
Sáiz‐Sapena, N., & Granell, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104966
Kapfhammer, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-68309-5_1
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Burhan, A. M., Goveas, D., Thiab, S., & Blair, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-53976-3_14
Research status of fetal hydrocephalus from 2003 to 2022 based on bibliometric analysis
Li, Q., Song, Z., Zhai, C., Hussain, S., Zhao, W., & Xiao, S. (2024) · Ibrain · doi:10.1002/ibra.12171
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Sun, L., Jiao, C.-C., Chen, Q., Wu, H. D., Wang, L.-Y., Liu, C.-H., Peng, Y., Zheng, C., Dai, S., Zhou, Q. Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5034329
A Review of the Progress in Clinical Application of Esketamine
黄, 芳. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123165
Sun, Z., Jiang, L., Xing, Y., & Luo, F. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099793
“24 Compared with ketamine, esketamine has a higher affinity for NMDA receptors, is more potent, induces fewer adverse effects such as sedation and cognitive impairment and is better tolerated.”
Zaremba, M., & Kleczkowska, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_17
Yamamoto, Y., Nakashima, M., & Suzuki, K. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43701
Uso de esketamina en depresión resistente al tratamiento: una revisión exploratoria sistemática
Rotta, C. E. D., Cornejo, E. S., Huayanay, L., & Vargas-Murga, H. (2025) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v88i3.6424
Ketamine for Conscious Sedation in Deep Brain Stimulation Surgery
Tamir, I., Kornilov, E., Erdman, H. B., & Bergman, H. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_25
Mehta, P., Starnes, C., Messias, E., & Grysman, N. (2025) · Springer eBooks · doi:10.1007/978-3-031-94645-5_7
Chen, B., Zhao, Y., Shen, N., Liu, F., Jiang, L., Ma, Y., Tian, X., & Kwan, P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.076
“Compared with ketamine (a race-mic mixture of different R-and S-enantiomers), esketamine has a higher affinity for NMDA receptors [44], thus fewer side effects and quicker clearance are evident due to the lower dose necessary to produce an equianesthetic effect.”
Aparicio-Mescua, T. (2022) · Institutional Repository of the University of Granada (University of Granada)
Rong, H.-T., 苏咸, & Wang, D. (2026) · BMC Anesthesiology · doi:10.1186/s12871-025-03597-8
“Esketamine is the S-enantiomer of racemic ketamine and exhibits 2-fold greater NMDA receptor affinity and potency than race-mic ketamine [27, 28].”
Henriques, C. A. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/kc0r-sm50
Olaoluwa, I. F. (2025) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2025-16871
Fonseca, É. P. F. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Esketamine use for treatment-resistant depression: a scoping review
Rotta, C. E. D., & Cornejo, E. S. (2024) · Universidad Peruana Cayetano Heredia Institutional Repository
Progress on the neurotrophic effects of antidepressant drugs
Jing, P., Liu, X.-C., Xiao-peng, Y. I. N., Fu, Y., Tian, Q., & (673328), X.-B. Z. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i4.115300
La kétamine, un antidépresseur d'action rapide et antagoniste du récepteur NMDA du glutamate
Nguyen, T. M. L. (2023) · theses.fr (ABES) · doi:10.70675/0ba94412ze24bz4514z9262z9ace4cb240c9
Khalifa, M. A., Altbali, S. M., Youssef, M. A., Saleh, A. O., Hashad, M. A., & Nosir, Y. A. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08687-1
“This short-term recovery score improvement may not only be due to its painkiller property but could also be due to its antidepressant and anxiolytic properties, mediated through upregulation of BDNF, TrkB activation, and stimulation of the mTOR pathway [18].”
Qasim, R., Mehmood, H., Raza, M., Tariq, Z., Mohib, K., Haseeb, B., Ahmed, A.-B., Hussain, A. A., Shakeel, I., Aminpoor, H., et al. (2026) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000103
Pharmacological and neurobehavioral evaluation of the bifunctional opioid peptide Gluten exorphin B5
Asokan, V., Jha, D. K., & Aranganathan, V. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118013
Kosiarski, B., Skrzypek, A., Markowicz, P., Zbrożek, M., Biłyk, K., Hutkowski, M., Chwostek, Z., Maruchniak, H., Marzec, W., & Biedroń, P. (2026) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/221219
“Esketamine, the S-enantiomer of racemic ketamine, represents a significant departure from traditional monoaminergic antidepressants by directly targeting the glutamatergic system [12].”
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_16
Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance
Li, D., Hsu, T.-W., Changchien, T.-C., Fang, Y.-Y., Yang, F.-C., Lin, H., & Liang, C.-S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122106
Cao, Z., Xue, H., Wang, H., & Liu, X. (2026) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s584512
Massetti, S., Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., Muller, K. A., Tzavara, E. T., Meerlo, P., Schoevers, R. A., & van Dalfsen, J. H. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122265
Chen, L., Chen, Y., Zhao, Y., Feng, T., Song, X., Xie, F., Shen, J., He, J., Guo, J., & Zhong, L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1781915
Ma, Y., Han, C., Sui, X., Lai, H., & Cao, X. (2026) · Research Square · doi:10.21203/rs.3.rs-10711679/v1
Sun, Y., Liu, F., Jia, L., Zhu, M., Yu, H., Huang, J., & Yu, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10648019/v1
Li, S., Zhou, W., Li, P., & Hu, Y. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000008380
Zhang, Z., Yin, G., He, W., Zhang, X., Wei, Y., Liang, X., Zhang, Z., & Zhou, X. P. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s631265
“13,14 However, the mechanisms by which it might suppress intraoperative erection—attenuation of spinal NMDA-mediated reflex pathways and sympathomimetic promotion of detumescence—remain hypotheses.”
Wang, Q., Zhang, J., Gu, J.-Q., Li, B., Gao, Y., Guo, F., Qi, Y., Li, Q., Luan, H., Gao, J., et al. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.08.039
Metadata
- Authors
- Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J.
- Affiliations
- Navarre Institute of Health Research (ES)
- Universitat Autònoma de Barcelona (ES)
- Universidad de Granada (ES)
- University of the Basque Country (ES)
- Corresponding author
- Molero, P.
- Venue
- CNS Drugs
- Published
- 2018-05
- Volume
- 32
- Issue
- 5
- Pages
- 411-420
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2800815779
- Cited by
- 280
- References
- 56
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 41 · 2023: 31 · 2022: 31 · 2021: 35 · 2020: 34 · 2019: 26 · 2018: 9
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, treatment-resistant depression, NMDA receptor, NR2B subunit, eEF2 kinase, brain-derived neurotrophic factor, mTOR signaling, intranasal administration, antidepressant tolerability, dissociative effects, antisuicidal effects, neurocognitive toxicity, substance use disorder risk, long-term safety
- MeSH terms
- Animals, Antidepressive Agents, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.